AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 FEB 13 - (NewsRx.com & NewsRx.net) -- Novogen, Ltd., (NVGN) has been issued the patent in the U.S. for human dietary supplements comprising soy material made from ground soy hypocotyl containing at least one isoflavone.
Novogen is a world leader in isoflavone technology and isoflavone products. Isoflavones can be extracted from a number of sources. Novogen uses the richest source, red clover, as the basis for its dietary supplement products Promensil, Rimostil, and Trinovin.
Novogen's intellectual property also extends to certain dietary supplements with isoflavones extracted from soy.
This new patent grant extends the cover for soy to include soy hypocotyls, which are an approved food and do not need to have the isoflavones chemically extracted.
Soy hypocotyls thus are a source of isoflavones for food products that might have health claims attached. The use of these alternative isoflavone sources derived from soy has been licensed from Novogen to DuPont Protein Technologies.
DuPont Protein Technologies launched a 70% joint venture with Bunge, Ltd., to be called Solae, LLC, with an expected initial annual revenue of $800 million and which will include the further ...